Agreement for Large-Scale Genotyping Studies
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Illumina, Inc. has announced that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK).
Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium™ assays to conduct genetic studies for thousands of samples provided by GSK.
The blanket agreement enables multiple projects to be conducted over period of time.
Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies.
